AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00928200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Due to the limited availability of Dexrazoxane (Zinecard®), treatment will be at the discretion of the treating physician. Dose should be 600 mg/m2 as a IV push immediately prior to anthracycline dose (the elapsed time from the beginning of the dexrazoxane dose to the end of the anthracycline infusion should be 30 minutes or less).
Study NCT04071522 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT03526120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pistachio
Description: Dailly 44 g unsalted pistachios snack for 12 weeks
Study NCT01203553 — intervention group
Intervention type: PROCEDURE
Intervention: Abdominal surgery
Description: Intraoperative mesh implantation
Study NCT04548622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Rapid 2 system triggering Magstim Super Rapid system
Description: Week 1 treatment includes rTMS for 5 sessions to both the left and right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
Study NCT03829332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03829332 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03829332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral capsule
Study NCT03829332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for lenvatinib
Description: oral capsule
Study NCT00964717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: real chiropractic
Description: real chiropractic manipulation
Study NCT00964717 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Chiropractic
Description: Placebo stimulation using 'activator' thumper
Study NCT02728986 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profore
Description: Profore multilayer compression bandage + standard regimen for wound care according to investigator's choice
Study NCT02728986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coban2
Description: Coban2 compression system + standard regimen for wound care according to investigator's choice
Study NCT02266420 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples of 10 mL
Description: Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
Study NCT00764868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate (LDX)
Description: optimal dose of 30, 50 or 70 mg once daily
Study NCT03701464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic naso-gallbladder drainage
Description: Using ERCP technique insert a naso-gallbladder drainage tube through common bile duct and cystic duct.
Study NCT03701464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous gallbladder drainage
Description: Percutaneous transhepatic technique insert drainage tube into gallbladder
Study NCT01231282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diffusion-weighted MRI
Description: MRI scan without contrast administration and without radiation exposure
Study NCT00597883 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: (non-experimental) carotid endarterectomy (CEA) for treatment of carotid artery stenosis
Study NCT00597883 — intervention group
Intervention type: OTHER
Intervention: Neurological and neuropsychological evaluations
Description: Clinical examinations consisting of a neurological and neuropsychological evaluation
Study NCT02027935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study NCT02027935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD8+ Melanoma Specific T Cells
Description: Given IV
Study NCT02027935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02027935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02027935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04141163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994. It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with other drugs under the names Actoplus Met, Metaglip, Glucovance, Janumet, Kombiglyze XR, and PrandiMet
Study NCT04141163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: No therapeutic effect
Study NCT01324882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with Olympus Technically Improved Colonoscope
Description: The standard colonoscopy will be performed using the Olympus Technically Improved Colonoscope.
Study NCT01324882 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control with standard colonoscope Olympus CF-H180
Description: Standard colonoscopy using the adult scope, Olympus CF-H180.
Study NCT04100356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise program - indoor bicycle interval exercise, duration 60 min 3x week
Study NCT04100356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Diet
Description: Normal diet recommended by the health authorities
Study NCT04100356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCHF Diet
Description: LCHF Diet, a modified Atkins diet with high percentage of fat and very low percentage of karbohydrates
Study NCT03286205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV iron
Description: IV iron infusion based on weekly or every 3 week dosage.
Study NCT02181699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK2823
Description: single agent KHK2823
Study NCT03971357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil
Description: netarsudil opthalmic solution 0.02%
Study NCT03971357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops
Study NCT01796977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OxyGenesys Dissolved Oxygen Dressing
Study NCT01796977 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Gauze Dressing
Study NCT00071643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
Study NCT00071643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
Study NCT00071643 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo pill.
Study NCT04228770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meeting with pharmacist
Description: Meeting with pharmacist to support drug management following their routine surgery.
Study NCT04708600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Articulation Resonance Therapy
Description: Goal: increase in lipspreading, forward tongue carriage, larynx elevation, forward resonance, precise articulation; 5 sessions Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory and visual discrimination of forward vs backed tongue carriage and lip spreading vs lip rounding)~* practice of technique on isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* practising larynx elevation through the twang technique, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* forward resonance, focusing on oral forward resonance rather than chest resonance, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* clear, precise articulation and cork exercise
Study NCT04708600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham therapy
Description: Goal: active sham treatment, 4 sessions Doses and duration: 4 one hour and 15 minutes sessions (5h), 4 weeks~Content:~* providing information about vocal function, vocal surgery, vocal hygiene, transgender health care~* discussing communication aspects and patterns, possible exercise contexts, communication partners, expectations of voice modification, conversational subjects~* active intervention on nonverbal communication (Kinesics, gestures and sign language, facial expression, haptics, proxemics, occulsics, and physical appearance)~* practising costo abdominal breathing patterns
Study NCT03157960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry drink
Description: Participant receive blueberry drink
Study NCT03157960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry and pizza
Description: Participant receive blueberry drink and a slice of pizza
Study NCT03157960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft beverage
Description: Participant receive a soft beverage drink
Study NCT03157960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft beverage and pizza
Description: Participant receive a soft beverage drink and a slice of pizza
Study NCT03157960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Participant receive a drink containing fructose
Study NCT03157960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose and pizza
Description: Participant receive a fructose drink and a slice of pizza
Study NCT03383471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Invossa K Inj.
Description: Invossa K Inj.
Study NCT03383471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT00994318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCM (Ferric carboxymaltose) high ferritin target
Study NCT00994318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCM (Ferric carboxymaltose) low ferritin target
Study NCT00994318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron (Ferrous sulphate)
Study NCT04306172 — intervention group
Intervention type: OTHER
Intervention: LACE+ score
Description: The LACE+ score is a point score that can be used to predict the risk of post-discharge death or urgent readmission. It was developed based on administrative data in Ontario, Canada.
Study NCT01039844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOC-paclitaxel
Description: Phase I Starting Dose: 100 mg/m\^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I.
Study NCT04306172 — intervention group
Intervention type: OTHER
Intervention: SQLAPE model
Description: The readmission risk model (Striving for Quality Level and analyzing of patient expenditures), is a computerized validated algorithm and was developed in 2002 to identify potentially avoidable readmissions.
Study NCT02836353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test
Study NCT02836353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
Study NCT01463891 — intervention group
Intervention type: DRUG
Intervention: Eribulin Mesylate
Description: The usual adult dose of eribulin mesylate is 1.4 mg/m\^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.
Study NCT01669824 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
Study NCT01000688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin + acarbose
Description: 4 week treatment
Study NCT01000688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acarbose + vildagliptin
Description: 4 week treatment
Study NCT04086524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binocular cartoon treatment at home
Description: see arm description.
Study NCT04086524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: see arm description
Study NCT04086524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binocular cartoon treatment in office
Description: see arm description.
Study NCT00559026 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Melan-A
Description: i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
Study NCT00559026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melan-A plus Dacarbazine
Description: Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
Study NCT03467282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
Study NCT03467282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1g polydextrose/maltodextrin - twice day
Study NCT00304434 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir
Study NCT00304434 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Probenecid
Study NCT04593303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal iliac artery ligation with cervicoisthmic compression suture
Description: Retroperitoneal approach will be performed to ligate both internal iliac arteries before bladder dissection followed by cervicoisthmic compression suture application at placental bed
Study NCT04593303 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cervicoisthmic compression suture without Internal iliac artery ligation
Description: Bladder dissection followed by cervicoisthmic compression suture application at placental bed without Internal iliac artery ligation
Study NCT02159287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour
Study NCT02159287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 1000 unit per hour continuous intravenous infusion of heparin sodium
Study NCT01151449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study NCT01151449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00152516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam (LEV)
Description: Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
Study NCT01479062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alive-PD
Description: Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support
Study NCT01479062 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Placebo Control
Study NCT01691430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 cranberry capsules
Description: Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
Study NCT01691430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
Study NCT01992874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib Capsule (Part A)
Description: Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
Study NCT01992874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib Tablet (Part A)
Description: Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
Study NCT01992874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib Tablet (Part A)
Description: Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
Study NCT02727413 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample collection
Description: Drawing of 10 ml blood at inclusion, at the time of CPB connection, 60 min under CPB, at the time of CPB disconnection, 6, 24 and 48 hours post-surgery
Study NCT01992874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib Capsule (Part A)
Description: Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
Study NCT01992874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib Capsule (Part B and trial extension phase)
Description: Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
Study NCT02798419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD05 Cream
Study NCT02798419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active01 Cream
Study NCT01223209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315
Description: 0.25-2.0 mg/ML, maximum 5 injections during 36 days.
Study NCT02260635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study NCT02260635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evacetrapib
Description: Administered orally
Study NCT02260635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02608476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01 cream, 1%
Description: CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Study NCT02608476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
Study NCT03793296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Device Closure: Vascular plug
Description: percutaneous transcatheter approach into cardiac valve
Study NCT04245358 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ainara
Description: 1g of gel per administration
Study NCT01465932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control, no Proprioception
Description: The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 1 (control group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff and cryotherapy.